Notes from the Peply team

Retatrutide in 2026: The Triple Agonist Explained

Retatrutide is Eli Lilly's Phase 3 investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Here's what the TRIUMPH data shows, how it compares to semaglutide and tirzepatide, and what regulatory status actually means in 2026.